Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...

GSK generated earnings per share of 23.2 pence last quarter, versus analysts’ average estimate of 20 pence. Last quarter, its ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

Appasamy Associates has appointed Annaswamy Vaidheesh as its non-executive chairman. With over 35 years of experience in the ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...